Trial Outcomes & Findings for Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity (NCT NCT01691560)

NCT ID: NCT01691560

Last Updated: 2014-05-29

Results Overview

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

140 participants

Primary outcome timeframe

Baseline to 4 weeks post administration of study treatment

Results posted on

2014-05-29

Participant Flow

Participants were recruited at the clinical site.

Out of 152 screened participants, 16 did not meet the study criterion while 2 withdrew consent. Hence, a total of 134 participants were randomized into the study.

Participant milestones

Participant milestones
Measure
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500 parts per million (ppm) fluoride as sodium monofluorophosphate
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Sodium Monofluorophosphate
Dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate
Sodium Fluoride
Dentifrice containing 1100 ppm fluoride as sodium fluoride
Overall Study
STARTED
34
33
34
33
Overall Study
COMPLETED
34
33
34
33
Overall Study
NOT COMPLETED
0
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=33 Participants
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate
Sodium Fluoride
n=33 Participants
Dentifrice containing 1100 ppm fluoride as sodium fluoride
Total
n=134 Participants
Total of all reporting groups
Age, Continuous
35.4 Years
STANDARD_DEVIATION 10.45 • n=5 Participants
33.2 Years
STANDARD_DEVIATION 10.13 • n=7 Participants
38.2 Years
STANDARD_DEVIATION 8.88 • n=5 Participants
36.2 Years
STANDARD_DEVIATION 9.62 • n=4 Participants
35.8 Years
STANDARD_DEVIATION 9.85 • n=21 Participants
Sex: Female, Male
Female
25 Participants
n=5 Participants
24 Participants
n=7 Participants
27 Participants
n=5 Participants
22 Participants
n=4 Participants
98 Participants
n=21 Participants
Sex: Female, Male
Male
9 Participants
n=5 Participants
9 Participants
n=7 Participants
7 Participants
n=5 Participants
11 Participants
n=4 Participants
36 Participants
n=21 Participants

PRIMARY outcome

Timeframe: Baseline to 4 weeks post administration of study treatment

Population: Intent to Treat (ITT) population: All randomized participants administered with at least one study treatment during the study and provided at least one post baseline assessment of efficacy.

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Outcome measures

Outcome measures
Measure
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate
Sodium Fluoride
n=33 Participants
Dentifrice containing 1100 ppm fluoride as sodium fluoride
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=33 Participants
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4
-0.36 Score on a scale
Interval -0.53 to -0.2
-0.43 Score on a scale
Interval -0.59 to -0.27
-0.40 Score on a scale
Interval -0.57 to -0.23
-0.45 Score on a scale
Interval -0.62 to -0.28

PRIMARY outcome

Timeframe: Baseline to 4 weeks post administration of study treatment

Population: ITT population: All randomized participants administered with at least one study treatment during the study and provided at least one post baseline assessment of efficacy.

Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.

Outcome measures

Outcome measures
Measure
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate
Sodium Fluoride
n=33 Participants
Dentifrice containing 1100 ppm fluoride as sodium fluoride
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=33 Participants
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4
7.31 grams
Standard Deviation 11.227
6.32 grams
Standard Deviation 13.045
4.09 grams
Standard Deviation 4.752
3.64 grams
Standard Deviation 6.030

PRIMARY outcome

Timeframe: Baseline to 8 weeks post administration of study treatment

Population: ITT population: All randomized participants administered with at least one study treatment during the study and provided at least one post baseline assessment of efficacy.

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Outcome measures

Outcome measures
Measure
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate
Sodium Fluoride
n=33 Participants
Dentifrice containing 1100 ppm fluoride as sodium fluoride
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=33 Participants
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8
-0.55 Score on a scale
Interval -0.78 to -0.33
-0.43 Score on a scale
Interval -0.66 to -0.2
-0.43 Score on a scale
Interval -0.66 to -0.2
-0.92 Score on a scale
Interval -1.15 to -0.68

PRIMARY outcome

Timeframe: Baseline to 8 weeks post administration of study treatment

Population: ITT population: All randomized participants administered with at least one study treatment during the study and provided at least one post baseline assessment of efficacy.

Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.

Outcome measures

Outcome measures
Measure
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate
Sodium Fluoride
n=33 Participants
Dentifrice containing 1100 ppm fluoride as sodium fluoride
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=33 Participants
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 8
10.15 grams
Standard Deviation 15.100
5.88 grams
Standard Deviation 11.512
4.39 grams
Standard Deviation 5.556
11.97 grams
Standard Deviation 16.486

PRIMARY outcome

Timeframe: Baseline to 4 weeks post administration of study treatment

Population: ITT population: All randomized participants administered with at least one study treatment during the study and provided at least one post baseline assessment of efficacy.

Participants rated the intensity of their response to the stimulus using a 10 point Visual rating scale of 1 (no Pain) to 10 (intense pain).

Outcome measures

Outcome measures
Measure
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate
Sodium Fluoride
n=33 Participants
Dentifrice containing 1100 ppm fluoride as sodium fluoride
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=33 Participants
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4
-1.22 Score on a scale
Interval -1.76 to -0.69
-1.07 Score on a scale
Interval -1.6 to -0.55
-1.35 Score on a scale
Interval -1.89 to -0.81
-1.25 Score on a scale
Interval -1.8 to -0.71

PRIMARY outcome

Timeframe: Baseline to 8 weeks post administration of study treatment

Population: ITT population: All randomized participants administered with at least one study treatment during the study and provided at least one post baseline assessment of efficacy.

Participants rated the intensity of their response to the stimulus using a 10 point VRS of 1 (no Pain) to 10 (intense pain).

Outcome measures

Outcome measures
Measure
5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Sodium Monofluorophosphate
n=34 Participants
Dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate
Sodium Fluoride
n=33 Participants
Dentifrice containing 1100 ppm fluoride as sodium fluoride
0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate
n=33 Participants
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500 ppm fluoride as sodium monofluorophosphate
Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8
-1.76 Score on a scale
Interval -2.35 to -1.17
-1.22 Score on a scale
Interval -1.81 to -0.63
-1.31 Score on a scale
Interval -1.9 to -0.71
-2.06 Score on a scale
Interval -2.67 to -1.46

Adverse Events

5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

0% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Sodium Monofluorophosphate

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Sodium Fluoride

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

  • Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER